Sigma Genetics
Healthspan
Seattle biotech building gene-delivery platforms (Fusogenix PLVs, Magnetoporator) and an in-situ CAR-T pipeline; YC- and grant-backed.
Sigma Genetics develops next-generation in-situ cell therapies and gene-delivery platforms. Its two core platforms are Fusogenix proteo-lipid vehicles (PLVs) — using FAST fusion proteins for direct cytosolic delivery in vivo/in situ, enabling repeat dosing and large DNA/RNA payloads — and the Magnetoporator, a scalable, high-viability magnetoporation system for ex-vivo cell engineering and manufacturing. It in-licenses clinically validated therapies from leading institutions to accelerate novel programs from concept to clinic. Its lead therapeutic focus is a redosable, dual-target in-situ CAR-T program for pan-cancer solid tumours, followed by an ethically derived trophoblast-stem-cell producer line for regenerative medicine and therapeutic biomanufacturing. The company positions itself as a foundational delivery engine for cellular therapies.
Research mapping
Healthspan / Intervene (AI) / A
Evidence boundary
Original analysis and independent corroboration remain under development. Commercial scale and durable technical advantage remain under review.
What makes it defensible
Fusogenix proteo-lipid vehicles enable human-safe, repeat-dosed in-vivo gene delivery with large payloads; Magnetoporator enables scalable, high-viability ex-vivo engineering.
Position in the stack: Gene-delivery engine layer — supplies delivery platforms (plus an in-situ CAR-T pipeline) that other cell-therapy developers and manufacturers build on.
Who buys it
Founding team
Zachary Rapp — Co-founder & CEO — CEO of Sigma Genetics
Matthew Scholz — Co-founder — Serial gene-therapy entrepreneur; holds patents in transfection technologies
Chris Pihl — Co-founder — Co-founder and board member
SourceFinancing detail
- Last round
- Series A
Investors: Westcott Investment Group; Ikarian Capital; SNBL
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Evidence & media
-
Sigma Genetics Inc. — Capital Factory portfolio profile
What this source supports: Capital Factory (All Access Fund 2025) portfolio profile: Sigma Genetics develops next-generation in situ CAR-T therapies plus gene-delivery platforms (Fusogenix Proteo-Lipid Vehicles, Magnetoporator).
What it does not establish: No funding amount, valuation, named customers, or clinical data; the company website is still a pre-launch placeholder.
Source -
Sigma Genetics Inc. — STATION Austin profile
What this source supports: STATION Austin profile: magnetoporation platform for scalable, high-viability cell engineering across immunotherapies, blood products and biomanufacturing.
What it does not establish: Marketing summary only; no third-party validation of performance claims.
Source -
Sigma Genetics Inc. — Austin Startups profile
What this source supports: Austin Startups profile lists company-reported pipeline POC: in vivo PLV CD19 CAR-T drove B-cell depletion in mice; Magnetoporation delivered >22x more live cells than electroporation.
What it does not establish: Preclinical results are company-supplied; no peer-reviewed publication or IND on file.
Source